Perimeter's AI-Powered Claire Wins FDA Nod for Breast Cancer Surgery
Event summary
- Perimeter Medical Imaging AI's Claire received FDA premarket approval (PMA) for intraoperative breast cancer margin assessment, the first AI-enabled imaging device of its kind in the U.S.
- Claire demonstrated 88.1% margin accuracy and a statistically significant reduction in residual cancer post-surgery in its pivotal trial.
- The technology combines optical coherence tomography (OCT) with AI trained on over 2 million breast tissue images.
- Perimeter plans a nationwide launch of Claire in the coming weeks.
- The pivotal trial was supported by a $7.4 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
The big picture
Perimeter's FDA approval positions it at the forefront of AI-enabled intraoperative imaging, addressing a significant unmet need in breast cancer surgery. The approval marks the first commercialization of its proprietary OCT-AI platform, targeting an estimated 300,000 annual U.S. breast cancer surgeries. This milestone could set a precedent for AI-driven innovations in other surgical and diagnostic applications, potentially reshaping the standard of care in oncology.
What we're watching
- Adoption Pace
- How quickly surgeons will integrate Claire into standard practice, given the 20% national average of repeat surgeries in breast-conserving procedures.
- Market Expansion
- Whether Perimeter can leverage its OCT-AI platform to expand into additional cancer indications beyond breast surgery.
- AI Enhancements
- The pace at which Perimeter will implement planned AI enhancements under its pre-determined change control plan (PCCP).
Related topics